IRINOTECAN WITH BIWEEKLY, LOW DOSE LEUCOVORIN AND BOLUS AND CONTINUOUS INFUSION 5-FLUOROURACIL (MODIFIED FOLFIRI) AS FIRST LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER

被引：0
|
作者：
Oh, S. Y. [1 ]
Kim, B. G. [1 ]
Kwon, H. [1 ]
Lee, S. [1 ]
Lee, D. M. [1 ]
Jang, J. S. [1 ]
Kim, M. C. [1 ]
Kim, S. [1 ]
Kim, H. [1 ]
机构：
[1] Dong A Univ, Coll Med, Pusan, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [31] Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
    Seo, Myung-Deok
    Lee, Keun-Wook
    Lim, Joo Han
    Yi, Hyeon Gyu
    Kim, Dae-Young
    Oh, Do-Youn
    Kim, Jee Hyun
    Im, Seock-Ah
    Kim, Tae-You
    Lee, Jong Seok
    Bang, Yung-Jue
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (09) : 589 - 595
  • [32] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen
    Sendur, Mehmet Ali Nahit
    Ozdemir, Nuriye
    Ozatli, Tahsin
    Yazici, Ozan
    Aksoy, Sercan
    Ekinci, Ahmet Siyar
    Yazilitas, Dogan
    Gunaydin, Yusuf
    Oksuzoglu, Berna
    Benekli, Mustafa
    Zengin, Nurullah
    MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 8
  • [34] Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen
    Mehmet Ali Nahit Sendur
    Nuriye Ozdemir
    Tahsin Özatlı
    Ozan Yazıcı
    Sercan Aksoy
    Ahmet Şiyar Ekinci
    Doğan Yazılıtaş
    Yusuf Günaydın
    Berna Oksuzoglu
    Mustafa Benekli
    Nurullah Zengin
    Medical Oncology, 2014, 31
  • [35] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Jeeyun Lee
    Kyung Hae Jung
    Young Suk Park
    Joong Bae Ahn
    Sang Jun Shin
    Seock-Ah Im
    Do Youn Oh
    Dong Bok Shin
    Tae Won Kim
    Namsu Lee
    Jae Ho Byun
    Yong Sang Hong
    Joon Oh Park
    Se Hoon Park
    Ho Yeong Lim
    Won Ki Kang
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 657 - 663
  • [36] The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens
    Kaya, Ali Osman
    Coskun, Ugur
    Gumus, Mahmut
    Dane, Faysal
    Ozkan, Metin
    Isikdogan, Abdurrahman
    Alkis, Necati
    Buyukberber, Suleyman
    Yumuk, Fulden
    Budakoglu, Burcin
    Demirci, Umut
    Berk, Veli
    Bilici, Ahmet
    Inal, Ali
    Arpaci, Erkan
    Benekli, Mustafa
    JOURNAL OF CHEMOTHERAPY, 2012, 24 (04) : 217 - 220
  • [37] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Lee, Jeeyun
    Jung, Kyung Hae
    Park, Young Suk
    Ahn, Joong Bae
    Shin, Sang Jun
    Im, Seock-Ah
    Oh, Do Youn
    Shin, Dong Bok
    Kim, Tae Won
    Lee, Namsu
    Byun, Jae Ho
    Hong, Yong Sang
    Park, Joon Oh
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 657 - 663
  • [38] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Shouji, Daigo
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keisho
    Oya, Masatoshi
    Yamaguchi, Toshiharu
    Muto, Tetsuichiro
    Hatake, Kiyohiko
    JOURNAL OF GASTROENTEROLOGY, 2008, 43 (11) : 842 - 848
  • [39] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
    Mitsukuni Suenaga
    Nobuyuki Mizunuma
    Daigo Shouji
    Eiji Shinozaki
    Satoshi Matsusaka
    Keisho Chin
    Masatoshi Oya
    Toshiharu Yamaguchi
    Tetsuichiro Muto
    Kiyohiko Hatake
    Journal of Gastroenterology, 2008, 43 : 842 - 848
  • [40] 5-Fluorouracil/Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) as First-Line Treatment of Advanced Gastric Cancer
    Grande, C.
    Martinez, M.
    Villanueva, M. J.
    Huidobro, G.
    Casal, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S469 - S469
12345